Exenatide (Byetta ®) Regulation of Intestinal and Hepatic Lipoprotein Particle Production in Humans
Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
Exenatide acutely inhibits intestinal lipoprotein particle production. We are unable to
speculate whether exenatide affects hepatic lipoprotein production in humans since there is
currently no evidence from animal models or in vitro studies that have demonstrated an effect